| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() ACR: Actonel (Risedronate) Once-a-Week Proves Equally Effective as Actonel Daily In Postmenopausal Osteoporosis SAN FRANCISCO, CA -- November 13, 2001 -- A once-a-week dosage of Actonel® (risedronate sodium tablets) 35 mg was as effective as daily Actonel 5 mg at increasing bone mineral density (BMD) in women with postmenopausal osteoporosis (PMO), in a recent study. Data from the study, which included 1,456 women age 50 and older, were presented today at the 65th Annual Scientific Meeting of the American College of Rheumatology (ACR) in San Francisco, California. In the study, patients taking Actonel 35 mg once a week experienced a significant 3.9 percent increase in lumbar spine BMD at 12 months versus baseline, comparable to the 4 percent increase achieved with the 5 mg daily dose. Total hip, femoral neck and trochanteric BMD also increased significantly at 12 months versus baseline with both dosages, with differences in BMD increases of less than 0.5 percent between the daily and once-a-week treatments. In addition, the adverse event profile of risedronate 35 mg once a week was comparable to the 5 mg daily dose. The study included postmenopausal women at least 50 years old with osteoporosis (defined as low lumbar spine BMD, or t-score less than or equal to -2.0 with at least one prior vertebral fracture). All women received calcium supplementation, and some received vitamin D if baseline levels were low. "These data suggest that once a week use of 35 mg risedronate may be an alternative to daily dosing," said Robert Lindsay, M.D., Ph.D., Helen Hayes Hospital, principal investigator of the study. "I expect that once a week dosing will be an important option for some patients and physicians." SOURCE: Aventis Pharmaceuticals Related Link: Aventis Pharmaceuticals.
|